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tricular systolic and diastolic functions, mass and geome-
try by using conventional echocardiography and pulsed
wave tissue Doppler imaging in individuals with MS
compared to healthy subjects.
Methods: The study included 120 subjects divided
by half into control and case group: 60 subjects (30 males
and 20 females) with MS (diagnosed according to consen-
sus statement from the International Diabetes Federation
(platinum standard)) aged 54.4 ± 9.5 years and 60 healthy
subjects (32 males and 28 females) aged 50.3 ± 13.7 years.
Left ventricular ejection fraction (LVEF) was measured
with the Tiech method in the short axis parasternal view
by averaging measurements from five consecutive car-
diac cycles. The LV diastolic function was estimated with
Doppler measurement of transmitral blood flow and
determination of the maximal rates for E and A peaks,
E/A ratio, delay time (DT) for early diastolic filling rate,
E0, A0 and E0/A0 ratio according to criteria of the European
Study Group on diastolic heart failure. IMP was be calcu-
lated as the sum of IVRT and IVCT divided by ventricular
ET (IMP = IVRT + IVCT/ET). LV mass was determined
using the corrected cube formula as (0.80  {1.04  [(sep-
tal thickness + LV internal diameter + posterior wall
thickness)3  (LV internal diameter)3]} + 0.6).
Results: The assessed parameters using conven-
tional and tissue Doppler echocardiography showing that
those with metabolic syndrome had greater LV mass and
significantly lower E/A ratio; increased LVH and signifi-
cantly higher IMP, indicating impaired global left ven-
tricular functions in patients with MS compared with
control subjects without MS. There were no statistically
significant difference in EF percentage.
Conclusions: Our results demonstrate that LV func-
tions are impaired in patients with metabolic syndrome
using IMP and E/A ratio. LVH incidence are higher in
metabolic syndrome patients. To conclude metabolic syn-
drome are associated with significant cardiac functions
deterioration and should be prevented and treated in
proper manner.
http://dx.doi:10.1016/j.jsha.2012.06.215
HCV Cardiomyopathy; raising a regional alert
A. Saleh, A. Matsumori, H. Negm, M. Shalaby, M.
Haykal, W. Sayed
Introduction: The global prevalence of Hepatitis C
Virus ‘‘HCV’’ carriers is estimated to average 3%, ranging
from 0.1% toP10% among different countries, 17–30% of
them complain of HCV Cardiomyopathy.
Objectives: To raise regional awareness of HCV as a
cardiotropic virus through sharing four stages of our
HCV Cardiomyopathy research.
Methodology: Fifty HCV positive patients with 50
controls were enrolled in first stage where conventional
echocardiography was used to evaluate LV systolic and
diastolic function. Tissue Doppler imaging was used in
the second stage to evaluate 30 HCV patients and 30 con-
trols. Forty five HCV positive patients with 45 controls
were evaluated by Strain Rate Imaging to assess left atrial
tissue dynamics in addition to measuring NTproBNP. At
our fourth stage, we evaluated combined antiviral and
anti-inflammatory therapy in 13 patients complaining of
HCV Cardiomyopathy. Speckle tracking echocardiogra-
phy was our tool to assess myocardial function before
and after administration of therapy.
Results: HCV group showed significant increase in
QTc interval, significant increase in A wave, Deceleration
time in addition to highly significant decrease in tissue
DopplerEa, highly significant decrease inAa andhighly sig-
nificant increased E/Ea ratio. Evaluation of Left atrial func-
tion revealed significant increase in left atrial ejection
fraction, ejection time, ejection force. Significant improve-
ment of global myocardial strain was showed after admin-
istration of therapy in patientswithHCVCardiomyopathy.
Conclusion: HCV is a cardiotropic virus. HCV
derived heart diseases are chronic and devastating dis-
eases. The combined anti-viral and anti-inflammatory
treatment may cure HCV derived cardiomyopathy.
http://dx.doi:10.1016/j.jsha.2012.06.216
Left main stenting, a short and intermediate fol-
low-up
A. Farah, M.-A. Ohlow, B. Lauer, A. Zaki, M.
Rashwan, M. Sobhy
Background: Significant left main coronary artery
disease occurs in about 5–7% of patients undergoing cor-
onary angiography. Coronary artery bypass graft (CABG)
surgery was the standard acceptable way in treating
these lesions. The introduction of drug eluting stents
(DES) in mid 2003 has pushed the rate of clinical resteno-
sis below 5% for most lesion types. This encourged the
cardiologists to treat the LMCA with DES.
Methods and results: We implanted DES in 30
patients with denovo LMCA-Stenosis (middle age
69.9 ± 12.5 83% men). 25 patients (83%) had hypertension,
5 diabetes mellitus (17%), 22 hyperlipidemia (73.3%) and
16 were smokers (53.3%). We implanted Paclitaxel-Stents
in 26 (87%) and 4 Sirolimus-Stents (13%). 11 patients
(37%) with Stents <16 mm. In 14 patients (47%) were dis-
tal LM (Bifurkation) and in 16 (53%) ostium or schaft.
Details of intervention technique (T-Stenting, V-Stenting,
Culotte and Y-Stenting) was left to the examiner. During
the followup (middle duration 6 months; range 4–
12 months) were no myocardial infarctions, Stent throm-
bose or death documented. In 4 patients (13.3%) was a
re-revascularisation procedure mandatory (1 CABG, 3
re-interventionen), without significant difference between
distal or non-distal lesions, type or lenght of stent.
Conclusion: LMCA intervention is in the hands of
experienced interventionalist technically possible and
sure (without MACE), connected with an accepted rate
of re-intervention.
http://dx.doi:10.1016/j.jsha.2012.06.217
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